{{'Search' | translate}}
 

FuGENE HD

Company: Promega
Catalog#: E4981
Bio-protocol()
Company-protocol()
Other protocol()

Equilibrium and Kinetic Measurements of Ligand Binding to HiBiT-tagged GPCRs on the Surface of Living Cells
Author:
Date:
2020-12-20
[Abstract]  

G-protein coupled receptors (GPCRs) remain at the forefront of drug discovery efforts. Detailed assessment of features contributing to GPCR ligand engagement in a physiologically relevant environment is imperative to the development of new therapeutics with improved efficacy. Traditionally, binding properties such as affinity and kinetics were obtained using biochemical radioligand binding assays. More recently, the high specificity of resonance energy transfer has been leveraged toward the development of homogeneous cell-based proximity assays with capacity for real-time kinetic measurements. This suite of ligand binding protocols couples the specificity of bioluminescent resonance energy transfer (BRET) with the sensitivity afforded by the luminescent HiBiT peptide. The BRET format is

...
[摘要]  [摘要] G蛋白偶联受体(GPCR)仍然是药物发现工作的最前沿。对有助于GPCR配体参与生理相关环境的特征进行详细评估,对于开发具有更高功效的新疗法至关重要。传统上,使用生化放射性配体结合测定法获得结合特性,如亲和力和动力学。最近,共振能量转移的高特异性已利用向homogen发展Ë容量进行实时动态测量的OU基于细胞的邻近分析。这套配体结合方案将生物发光共振能量转移(BRET)的特异性与发光HiBiT肽提供的灵敏度相结合。BRET格式用于通过与荧光示踪剂的竞争性结合来定量配体与其同源HiBiT标签GPCR之间的动态相互作用。同时,HiBiT与细胞不可渗透的LgBiT的高亲和力互补将明亮的生物发光供体信号限制到细胞表面,并消除了细胞内区室中未被占用的受体的发光背景。


[背景] G蛋白偶联受体(GPCR)在驱动细胞信号传导途径中起关键作用,并且仍然是药物开发的重要目标类别(Santos等,2017)。因此,对于基础研究和药物发现运动而言,可以定量对于药物作用至关重要的生物物理特性的GPCR配体结合测定法是必不可少的(Fang,2012; ...

Comments